R&D channel feed – Endpoints News

R&D channel feed

Updated: Novartis axes PhIII peanut allergy trial, expects to test 'optimized dosing' in new trial later this year

Last year

Roche's TIGIT win limited by standard of care change, lack of global study

Last year

Regenxbio touts positive mid-stage data for AbbVie-partnered vision-loss gene therapy, but no detailed plans for pivotal study

Last year

Merck adds third cervical cancer nod for Keytruda, bringing total approvals to 39

Last year

Looking past COPD, Regeneron CSO George Yancopoulos says Dupixent's 'next big thing' is reversing allergies

Last year

Allakos halves workforce, drops lead inflammatory program

Last year

Dyne closes $345M public offering a week after early positive data for dystrophy drugs

Last year

Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal: #JPM24

Last year

#JPM24 quick hits: Ionis on partnership’s pros and cons; Novo Ventures has $600M to spend; Are small molecules back? + more

Last year

Sanofi says it may look at next generation of weight loss drugs: #JPM24

Last year

After 'growing up' last year, Moderna warns of losses and charts path back to profits: #JPM24

Last year

Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout

Last year

C4 Therapeutics cuts staff, restructures to focus on lead protein degradation programs, discovery pacts

Last year

Alcon touts PhIII win for dry eye drug, plans mid-2024 FDA filing

Last year

Blueprint to pull Gavreto in certain markets, shelve EGFR programs as it focuses on Ayvakit launch

Last year

Jennifer Doudna, Fyodor Urnov want to streamline gene editing studies with Danaher's help

Last year

#JPM24 quick hits: A 'great year for M&A'; an optimistic Sarepta; Pfizer's CEO + more

Last year

Pfizer CEO says it's back to basics after painful 2023 for investors: #JPM24

Last year

Exelixis cuts 175 staffers to prioritize late-stage drug development

Last year

Bayer’s $425M non-hormonal therapy for menopause symptoms clears first PhIII test

Last year

Affimed cuts up to 50% of employees to support clinical projects, CEO departs

Last year

Novartis licenses two cardiovascular RNAi drugs from Chinese biotech for $185M upfront

Last year

Vertex pauses diabetes islet cell therapy study after two patient deaths it says are unrelated to drug

Last year

'If you could have the next Prozac, that’s intoxicating': Sage’s postpartum depression triumph and the failure that followed

Last year

First page Previous page 57 58 596061 62 63 Next page Last page